全文获取类型
收费全文 | 56231篇 |
免费 | 5599篇 |
国内免费 | 126篇 |
专业分类
耳鼻咽喉 | 560篇 |
儿科学 | 1463篇 |
妇产科学 | 1265篇 |
基础医学 | 8298篇 |
口腔科学 | 1404篇 |
临床医学 | 7060篇 |
内科学 | 10136篇 |
皮肤病学 | 624篇 |
神经病学 | 5391篇 |
特种医学 | 2112篇 |
外国民族医学 | 57篇 |
外科学 | 6978篇 |
综合类 | 1138篇 |
一般理论 | 51篇 |
预防医学 | 6352篇 |
眼科学 | 1433篇 |
药学 | 4205篇 |
中国医学 | 33篇 |
肿瘤学 | 3396篇 |
出版年
2021年 | 761篇 |
2020年 | 505篇 |
2019年 | 807篇 |
2018年 | 867篇 |
2017年 | 688篇 |
2016年 | 773篇 |
2015年 | 846篇 |
2014年 | 1213篇 |
2013年 | 1956篇 |
2012年 | 2656篇 |
2011年 | 2821篇 |
2010年 | 1605篇 |
2009年 | 1440篇 |
2008年 | 2619篇 |
2007年 | 2689篇 |
2006年 | 2741篇 |
2005年 | 2652篇 |
2004年 | 2614篇 |
2003年 | 2342篇 |
2002年 | 2350篇 |
2001年 | 1633篇 |
2000年 | 1716篇 |
1999年 | 1491篇 |
1998年 | 716篇 |
1997年 | 642篇 |
1996年 | 556篇 |
1995年 | 561篇 |
1994年 | 510篇 |
1993年 | 480篇 |
1992年 | 1159篇 |
1991年 | 1224篇 |
1990年 | 1104篇 |
1989年 | 1091篇 |
1988年 | 1075篇 |
1987年 | 940篇 |
1986年 | 931篇 |
1985年 | 910篇 |
1984年 | 763篇 |
1983年 | 655篇 |
1982年 | 453篇 |
1981年 | 433篇 |
1980年 | 404篇 |
1979年 | 714篇 |
1978年 | 546篇 |
1977年 | 479篇 |
1976年 | 452篇 |
1975年 | 401篇 |
1974年 | 476篇 |
1973年 | 463篇 |
1972年 | 412篇 |
排序方式: 共有10000条查询结果,搜索用时 218 毫秒
1.
Heather L. Brown 《Journal of emergency nursing》2021,47(2):321-325
The coronavirus 2019 pandemic has affected almost every aspect of health care delivery in the United States, and the emergency medicine system has been hit particularly hard while dealing with this public health crisis. In an unprecedented time in our history, medical systems and clinicians have been asked to be creative, flexible, and innovative, all while continuing to uphold the important standards in the US health care system. To continue providing quality services to patients during this extraordinary time, care providers, organizations, administrators, and insurers have needed to alter longstanding models and procedures to respond to the dynamics of a pandemic. The Emergency Medicine Treatment and Active Labor Act of 1986, or EMTALA, is 1 example of where these alterations have allowed health care facilities and clinicians to continue their work of caring for patients while protecting both the patients and the clinicians themselves from infectious exposures at the same time. 相似文献
2.
3.
Liam Masterson James Howard Jazmina Gonzalez-Cruz Christopher Jackson Catherine Barnett Lewis Overton Howard Liu Rahul Ladwa Fiona Simpson Margie McGrath Ben Wallwork Terry Jones Christian Ottensmeier Melvin L.K. Chua Chris Perry Rajiv Khanna Benedict Panizza Sandro Porceddu Matt Lechner 《International journal of cancer. Journal international du cancer》2020,146(8):2305-2314
Now is an exciting era of development in immunotherapy checkpoint inhibitors and their effect on the treatment of NPC. While the general prognosis of R/M disease is poor, immunotherapy offers some promise in a malignancy associated with EBV and characterized by a peritumoural immune infiltrate. Our study aims to review past and on-going clinical trials of monoclonal antibody therapies against the checkpoint inhibitors (e.g. PD1 and CTLA-4), in R/M NPC. All randomized and nonrandomized controlled trials involving immune checkpoint inhibitor interventions for treatment of NPC were included in the study. We utilized a validated “risk of bias” tool to assess study quality. Four separate Phase I–II trials report the potential of PD1 inhibitor treatment for patients with NPC. Within the observed groups, camrelizumab combined with chemotherapy achieved an objective response in 91% of patients as first-line treatment for metastatic NPC (PFS 68% at 1-year) but this was associated with a high rate of grade >3 adverse events (87%; CTCAE version 4.03). The remaining three studies focused on recurrent NPC disease in patients who had received at least one line of prior chemotherapy. Within this group, camrelizumab monotherapy achieved an objective response in 34% of patients (PFS 27% at 1-year; range across all three studies 20.5–34%). No NPC trial has yet reported on specific outcomes for non-PD1 checkpoint inhibitors but 11 on-going studies include alternative targets (e.g. PD-L1/CTLA-4) as combination or monotherapy treatments. In considering checkpoint immunotherapies for NPC, initial results show promise for anti-PD1 interventions. Further phase I–III trials are in progress to clarify clinical outcomes, fully determine safety profiles, and optimize drug combinations and administration schedules. 相似文献
4.
5.
Osric A. Forrest Daniel M. Chopyk Yael Gernez Milton R. Brown Carol K. Conrad Richard B. Moss Vin Tangpricha Limin Peng Rabindra Tirouvanziam 《Journal of cystic fibrosis》2019,18(1):64-70
Background
Resistin is an immunometabolic mediator that is elevated in several inflammatory disorders. A ligand for Toll-like receptor 4, resistin modulates the recruitment and activation of myeloid cells, notably neutrophils. Neutrophils are major drivers of cystic fibrosis (CF) lung disease, in part due to the release of human neutrophil elastase- and myeloperoxidase-rich primary granules, leading to tissue damage. Here we assessed the relationship of resistin to CF lung disease.Methods
Resistin levels were measured in plasma and sputum from three retrospective CF cohorts spanning a wide range of disease. We also assessed the ability of neutrophils to secrete resistin upon activation in vitro. Finally, we constructed a multivariate model assessing the relationship between resistin levels and lung function.Results
Plasma resistin levels were only marginally higher in CF than in healthy control subjects. By contrast, sputum resistin levels were very high in CF, reaching 50–100 fold higher levels than in plasma. Among CF patients, higher plasma resistin levels were associated with allergic bronchopulmonary aspergillosis, and higher sputum resistin levels were associated with CF-related diabetes. Mechanistically, in vitro release of neutrophil primary granules was concomitant with resistin secretion. Overall, sputum resistin levels were negatively correlated with CF lung function, independently of other variables (age, sex, and genotype).Conclusions
Our data establish relationships between resistin levels in the plasma and sputum of CF patients that correlate with disease status, and identify resistin as a novel mechanistic link between neutrophilic inflammation and lung disease in CF. 相似文献6.
7.
8.
9.
10.
Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers 下载免费PDF全文